ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Time to Sell?

ImmuCell Corporation (NASDAQ:ICCC) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.23 and traded as high as $6.29. ImmuCell shares last traded at $6.2350, with a volume of 13,385 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of ImmuCell from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

ImmuCell Price Performance

The company has a quick ratio of 1.99, a current ratio of 3.85 and a debt-to-equity ratio of 0.28. The stock has a market cap of $56.40 million, a P/E ratio of 32.82 and a beta of 0.29. The firm has a 50 day moving average price of $6.22 and a 200 day moving average price of $6.23.

ImmuCell (NASDAQ:ICCC) last released its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a net margin of 6.23% and a return on equity of 6.25%. The company had revenue of $6.45 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC increased its position in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Geode Capital Management LLC owned about 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.